Endo Pharmaceuticals (Schizophernia Treatment) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Endo Pharmaceuticals (Schizophernia Treatment) General Information

Description

Medical formulation for treatment of schizophrenia. An implantable, six-month formulation of the atypical antipsychotic risperidone for treating schizophrenia and other serious psychiatric disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Therapeutic Devices
Acquirer
Primary Office
  • Simmonscourt Road, Ballsbridge
  • 1st Floor, Minerva House
  • Dublin 4
  • Ireland
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Endo Pharmaceuticals (Schizophernia Treatment) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Endo Pharmaceuticals (Schizophernia Treatment)‘s full profile, request access.

Request a free trial

Endo Pharmaceuticals (Schizophernia Treatment) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Endo Pharmaceuticals (Schizophernia Treatment)‘s full profile, request access.

Request a free trial